Crizotinib 250mg (Crizonix)

What is Crizonix 250mg?

Crizonix 250mg is a prescription medicine containing the ingredient Crizotinib, which is a tyrosine kinase receptor inhibitor. Crizonix 250mg is indicated for the treatment of patients with non-small cell lung cancer, either in advanced or metastatic stage of the disease.

Drug information Crizonix 250mg 

• Active ingredient: Crizotinib
• Content: 250mg.
• Drug class: Anticancer drugs, tyrosine kinase inhibitors.
• Dosage form: Capsules.
• Packaging:  Box of 28 tablets.
• Origin:  Bangladesh.

Pharmacological properties and mechanism of action

Pharmacology:

• Active ingredient Crizotinib is a tyrosine kinase receptor inhibitor that includes ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 (c-ros) and Recepteur d'Origine Nantais (RON). Translocations can affect the ALK gene leading to the expression of oncogenic fusion proteins.

Pharmacokinetics:

• Absorption: Following a single oral dose in the fasted state, crizotinib is absorbed with a mean time to peak concentrations of 4 to 6 hours.
• Distribution: 91% of crizotinib is bound to plasma proteins and is independent of drug concentration.
• Metabolism: crizotinib is metabolised by CYP3A4/5 enzymes.
• Elimination: Following a single radiolabelled dose of crizotinib 250 mg to healthy subjects, 63% and 22% of the administered dose was recovered in feces and urine, respectively.

Similar product

• Ibrunix 140mg
• IMBRUVICA